284 related articles for article (PubMed ID: 34311346)
1. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
Mondaca S; Lebow ES; Namakydoust A; Razavi P; Reis-Filho JS; Shen R; Offin M; Tu HY; Murciano-Goroff Y; Xu C; Makhnin A; Martinez A; Pavlakis N; Clarke S; Itchins M; Lee A; Rimner A; Gomez D; Rocco G; Chaft JE; Riely GJ; Rudin CM; Jones DR; Li M; Shaffer T; Hosseini SA; Bertucci C; Lim LP; Drilon A; Berger MF; Benayed R; Arcila ME; Isbell JM; Li BT
Lung Cancer; 2021 Sep; 159():66-73. PubMed ID: 34311346
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Sabari JK; Offin M; Stephens D; Ni A; Lee A; Pavlakis N; Clarke S; Diakos CI; Datta S; Tandon N; Martinez A; Myers ML; Makhnin A; Leger Y; Yu HA; Paik PK; Chaft JE; Kris MG; Jeon JO; Borsu LA; Ladanyi M; Arcila ME; Hernandez J; Henderson S; Shaffer T; Garg K; DiPasquo D; Raymond CK; Lim LP; Li M; Hellmann MD; Drilon A; Riely GJ; Rusch VW; Jones DR; Rimner A; Rudin CM; Isbell JM; Li BT
J Natl Cancer Inst; 2019 Jun; 111(6):575-583. PubMed ID: 30496436
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
[TBL] [Abstract][Full Text] [Related]
6. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
[TBL] [Abstract][Full Text] [Related]
8. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
10. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
11. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.
Lin Z; Li Y; Tang S; Deng Q; Jiang J; Zhou C
Lung Cancer; 2023 Aug; 182():107282. PubMed ID: 37392713
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J; Swalduz A; Planchard D; Ortiz-Cuaran S; Mezquita L; Lacroix L; Jovelet C; Rouleau E; Leonce C; De Kievit F; Morris C; Jones G; Mercier K; Howarth K; Green E; Pérol M; Saintigny P; Besse B
PLoS One; 2020; 15(6):e0234302. PubMed ID: 32525942
[TBL] [Abstract][Full Text] [Related]
16. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
17. The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.
Lee JK; Hazar-Rethinam M; Decker B; Gjoerup O; Madison RW; Lieber DS; Chung JH; Schrock AB; Creeden J; Venstrom J; Alexander B; Oxnard GR
Clin Cancer Res; 2022 Feb; 28(4):728-737. PubMed ID: 34753780
[TBL] [Abstract][Full Text] [Related]
18. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
